CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of Giulio Draetta, M.D., Ph.D., and Kai Wucherpfennig, M.D., Ph.D., recognized leaders in the fields of tumor biology and cancer immunotherapy. Enumeral is applying its proprietary immune profiling technology to enable the development of potential best-in-class antibodies against targets in immuno-oncology and other disease applications. The Company's lead program is focused on a next-generation PD-1 antibody, which is expected to enter clinical testing in 2016.